Changzhou Qianhong Bio Pharma Co., Ltd formulation plant
Changzhou Qianhong Bio Pharma Co., Ltd formulation plant is a drug establishment in Changzhou, China, registered with the US FDA under FEI 3005275502. Its registered operations are: Analytical testing. 3 EU/UK GMP certificates are matched to this site, 1 inspected within the last three years; 2 have since been withdrawn by the issuing authority. FDA has published 6 inspection outcomes for this FEI; the most recent, ended 31 Oct 2025, was classified voluntary action indicated (VAI).
Sources: FDA Drug Establishments Current Registration Site (checked 16 Nov 2026); FDA Data Dashboard (inspections); EudraGMDP; MHRA GMDP. Methodology
Cite as: PharmaTek, “Changzhou Qianhong Bio Pharma Co., Ltd formulation plant: FDA registration, inspection and GMP record (FEI 3005275502)”, record as of 16 Nov 2026, pharmatek.co.uk/manufacturing-sites/changzhou-qianhong-bio-pharma-co-ltd-formulation-plant-changzhou-3005275502
Registered operations
Business operations this establishment declares in its FDA registration. Registration is not an approval and says nothing about EU or UK GMP status.
GMP documents matched to this site (3)
| Document | Authority | Inspection | Source |
|---|---|---|---|
DE_HH_01_GMP_2026_0012 GMP certificate | Competent authority of Germany | 16 Apr 2026 within 3-year review window | EudraGMDP |
DE_HH_01_GMP_2023_0041 GMP certificate | Competent authority of Germany | 10 May 2023 Superseded by a newer certificate; withdrawn on 2 Oct 2023 Register note: GMP certificate has been superseded by document with the number DE_HH_01_GMP_2023_0042 | EudraGMDP |
DE_HH_01_GMP_2023_0042 GMP certificate | Competent authority of Germany | 10 May 2023 Superseded by a newer certificate; withdrawn on 22 May 2026 Register note: GMP certificate has been superseded by document with the number DE_HH_01_GMP_2026_0012 | EudraGMDP |
A GMP document is matched to this site when its address names the site's street and its city or postcode. In our latest internal review 59 of 60 sampled matches were the right site (not yet independently reviewed; measured match quality). Check the certificate's own address before relying on it. The three-year review window is the EMA guideline default after an inspection, not an official expiry date.
FDA inspection outcomes (6)
| Inspection ended | Outcome | Programme area | Citations posted |
|---|---|---|---|
| 31 Oct 2025 | VAI · Voluntary action indicated | Drug Quality Assurance | No |
| 10 May 2023 | VAI · Voluntary action indicated | Drug Quality Assurance | No |
| 23 Oct 2019 | NAI · No action indicated | Drug Quality Assurance | No |
| 15 Dec 2017 | VAI · Voluntary action indicated | Drug Quality Assurance | No |
| 1 Aug 2014 | VAI · Voluntary action indicated | Drug Quality Assurance | No |
| 30 Apr 2010 | NAI · No action indicated | Drug Quality Assurance | No |
FDA Data Dashboard, joined on the FEI. NAI: no objectionable conditions found. VAI: objectionable conditions found, but not serious enough for regulatory action. OAI: regulatory or administrative action recommended. A classification describes one inspection on one date; FDA publishes it only once final and does not publish every inspection. FDA firm profile
FDA warning letters (1)
- Warning letter issued 10 Jun 2013FDA warning letters
FDA Data Dashboard, drug products, issued against FEI 3005275502. A warning letter may since have been closed out; FDA publishes close-out letters separately.
What this page does not show
- Which substances are made here: DMFs and CEPs are filed by organisations, not sites, so we do not link substances to this site.
- Capacity, scale, price or current availability: no regulator publishes these.
- The full text of a Form 483 or warning letter: FDA's dashboard gives the regulation cited and a short description only.
Is this CHANGZHOU QIANHONG BIO PHARMA CO LTD?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.